MSFT, AZN, and BLK earn praise in fresh Zacks reports, with AI, pharma pipelines, and AUM growth fueling long-term outlooks.

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small ...

PFE's new drug launches and Seagen acquisition are driving revenue gains despite COVID declines and market headwinds.

AstraZeneca’s share price has fallen a lot from its September high, but this could mean a tremendous opportunity for me to ...

Cancer researchers discovered how exercise really can be like a drug for colon cancer, and AstraZeneca's immunotherapy drug ...

Download to gain expert insights and data-driven analysis from the ASCO 2025 Annual Meeting. This report covers key ...

The findings provide insight into which patients may have favorable or inferior responses to immunotherapy for small cell ...